Opko Health, Inc.

4400 Biscayne Boulevard,
Miami, Florida 33137
United States,
(305) 575-4100
www.opko.com

Opko Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Opko's diagnostics business includes Bio-Reference Laboratories, a clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Opko's pharmaceutical business includes Rayaldee, a treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. Opko's pharmaceutical business also includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection and a longer acting Factor VIIa drug for hemophilia. Opko Health, Inc. was formed in 2007 and is based in Miami, Florida.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.0/yr) # 14 2 2 1 - - 19
vol $500M $1.5B $60M $2.0B
Sell (0.2/yr) # 1 - - - 1 - 2
  21

Top M&A Advisors

Financial Deals
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
1
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Bio-Reference Laboratories, Inc.
$1.5B (2015-08-20)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View

According to our data here at Mergr, Opko Health has acquired 19 companies, including 5 in the last 5 years. It has also divested 2 assets.

Opko Health’s largest acquisition to date was in 2015, when it acquired Bio-Reference Laboratories for $1.5B. Opko Health has acquired in 5 different US states, and 9 countries. The Company’s most targeted sectors include medical products (53%) and life science (43%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 405 life science companies that have made at least 1 acquisition, 14 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 30 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 6 platform acquisitions.

Join Mergr and gain access to Opko Health’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.4K Private Equity Firms
  • 121K M&A Transactions
  • 131K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.